Saranac Partners’s AstraZeneca AZN Stock Holding History

Saranac Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$846K	Sell	4,522 -1,049	-19%	-$197K	0.25%	54
2026 Q1	$987K	Buy	+5,571	New	+$1.07M	0.42%	42
2025 Q4	–	Sell	-2,909	Closed	-$876K	–	86
2025 Q3	$876K	Buy	+2,909	New	+$440K	0.16%	91

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Saranac Partners's AZN Position: Q2 2026 in Review

Saranac Partners reduced its AstraZeneca (AZN) stake by 19% in Q2 2026, selling an estimated $197K and leaving 4,522 shares worth $846K. The position accounts for 0.25% of the portfolio, ranked #54.

Saranac Partners first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. The position peaked at $987K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Saranac Partners held 4,522 shares of AstraZeneca worth $846K as of Q2 2026.
Saranac Partners sold 1,049 AstraZeneca shares in Q2 2026, an estimated $197K.
AstraZeneca made up 0.25% of Saranac Partners's portfolio in Q2 2026, its #54 holding.
Saranac Partners first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
Saranac Partners's AstraZeneca position peaked at $987K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.